A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
This study is conducted to determine the safety and tolerability of INCB161734 as a single agent or in combination with other anticancer therapies.
Checked against the public recordLast updated Jul 22, 2026 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- Incyte Corporation
- Interventions being studied
- Drug: INCB161734; Drug: Cetuximab; Drug: Retifanlimab; Drug: GEMNabP; Drug: mFOLFIRINOX; Drug: FOLFOX; Drug: FOLFIRI; Drug: INCA33890
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * ≥18 years old. * Locally advanced or metastatic solid tumor with KRAS G12D mutation. * For Part 1a and Part 2 Combination Groups 1, 2, and 7: Disease progression on prior standard treatment, intolerance to or ineligibility for standard treatment, declined available therapies that are known to confer clinical benefit, or no standard available treatment to improve the disease outcome. * Cohort specific requirements aas defined in the protocol. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Exclusion Criteria: * Prior treatment with any KRAS G12D inhibitor * Known additional invasive malignancy within 1 year of the first dose of study drug * History of organ transplant, including allogeneic stem cell transplantation * Significant, uncontrolled medical condition * History or presence of an ECG abnormality * Inadequate organ function Other protocol-defined Inclusion/Exclusion Criteria may apply
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Mayo Clinic HospitalPhoenix, Arizona
- Stanford UniversityPalo Alto, California
- UCLA Healthcare Hematology-OncologySanta Monica, California
- Sarah Cannon Research Institue At HealthoneDenver, Colorado
- Florida Cancer SpecialistsSarasota, Florida
- Sidney Kimmel Comprehensive Cancer Center At Johns HopkinsBaltimore, Maryland
- Dana Farber Cancer InstituteBoston, Massachusetts
- Hackensack University Medical CenterHackensack, New Jersey
- Weill Cornell MedicineNew York, New York
- Memorial Sloan Kettering Cancer CenterNew York, New York
- Jefferson University HospitalsPhiladelphia, Pennsylvania
- Scri Oncology PartnersNashville, Tennessee
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jul 22, 2026. Always confirm current availability with the study team.